Betting big on peptides “Peptide-based drugs made up only five percent of the global pharmaceutical market in 2019, but this still accounts for an enormous USD 60 billion total market size.
Peptides are a growing field in which interest has fluctuated over the years,” begins Toniatti. “There was a lot of excitement around peptides in the past, but some technological limitations, including, for example, poor pharmacokinetic profiles (i.e., short-half life in the body), and the cost of large-scale manufacturing, resulting in the commercial development of peptides with agonistic activity within a relatively narrow number of therapeutic indications.
Recent big investments into peptide-based platforms include Takeda’s setting aside of USD 3.5 billionin its partnership with Japanese peptide conjugate maker PeptiDream…”
https://pharmaboardroom.com/articles/peptides-technological-maturity-leading-to-big-investments-breakthroughs/